RTI-336

Last updated

RTI-336
RTI-336.svg
Identifiers
  • 5-[(1S,3S,4S,5R)-3-(4-Chlorophenyl)-8-methyl-8-azabicyclo[3.2.1]octan-4-yl]-3-(4-methylphenyl)-1,2-oxazole
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
Formula C24H25ClN2O
Molar mass 392.93 g·mol−1
3D model (JSmol)
  • CC1=CC=C(C=C1)C2=NOC(=C2)[C@@H]3[C@H]4CC[C@H](N4C)C[C@@H]3C5=CC=C(C=C5)
  • InChI=1S/C24H25ClN2O/c1-15-3-5-17(6-4-15)21-14-23(28-26-21)24-20(16-7-9-18(25)10-8-16)13-19-11-12-22(24)27(19)2/h3-10,14,19-20,22,24H,11-13H2,1-2H3/t19-,20+,22+,24-/m0/s1
  • Key:AUXUFNHAVGIVDC-IKJKNFHUSA-N

RTI-336, also known as RTI-4229-336 or LS-193,309 is a potent and selective dopamine reuptake inhibitor that was initially developed by the Research Triangle Institute, now known as RTI International. [1]

Contents

Pharmacology

It is a phenyltropane derivative that binds to the dopamine transporter with approximately 20 times the affinity of cocaine. [2] However, it produces relatively mild stimulant effects, with a slow onset and a long duration of action. [3] (Although, other sources classify it as having among the faster onsets of action among phenyltropanes. [4] )

Affinity of RIT-336 and analogs for the main monoamine transporters (DAT, NET, SERT): [1]

RTIXR[3H]CFT[3H]Nisoxetine[3H]ParoxetineN ÷ DS ÷ D
Coc——89.13298 (1986)1045 (45)37.0111.79
177Clphenyl1.28504 (304)2420 (220)393.81891
176Mephenyl1.58398 (239)5110 (465)251.93234
354Meethyl1.62299 (180)6400 (582)184.63951
336Clp-tolyl4.091714 (1033)5741 (522)419.11404
386Mep-anisyl3.93756 (450)4027 (380)192.41025

Animal studies

These characteristics make it a potential candidate for the treatment of cocaine addiction, as a possible substitute drug, analogous to the use of methadone for treating heroin dependence. [1] [5] RTI-336 fully substitutes for cocaine in addicted monkeys and supports self-administration, [4] [6] and significantly reduces rates of cocaine use, especially when combined with SSRIs. [7] Research is ongoing to determine whether it could be a viable substitute drug in human cocaine addicts.

RTI-336 and RTI-177 exhibited lower reinforcing strength than cocaine in nonhuman primates, indicating reduced abuse liability and supporting their viability as pharmacotherapies for addiction. [8]

Chronic RTI-336 administration in rhesus monkeys altered motor activity and sleep patterns but did not cause adverse hormonal changes, suggesting a relatively safe profile for long-term therapeutic use. [9]

Clinical studies

A dosage of up to 20mg has been tolerated in healthy males. [10]

See also

References

  1. 1 2 3 Carroll FI, Howard JL, Howell LL, Fox BS, Kuhar MJ (March 2006). "Development of the dopamine transporter selective RTI-336 as a pharmacotherapy for cocaine abuse". The AAPS Journal. 8 (1): E196 –E203. doi:10.1208/aapsj080124. PMC   2751440 . PMID   16584128.
  2. ↑ Carroll FI, Pawlush N, Kuhar MJ, Pollard GT, Howard JL (January 2004). "Synthesis, monoamine transporter binding properties, and behavioral pharmacology of a series of 3beta-(substituted phenyl)-2beta-(3'-substituted isoxazol-5-yl)tropanes". Journal of Medicinal Chemistry. 47 (2): 296–302. doi:10.1021/jm030453p. PMID   14711303.
  3. ↑ Carroll FI, Fox BS, Kuhar MJ, Howard JL, Pollard GT, Schenk S (December 2006). "Effects of dopamine transporter selective 3-phenyltropane analogs on locomotor activity, drug discrimination, and cocaine self-administration after oral administration". European Journal of Pharmacology. 553 (1–3): 149–156. doi:10.1016/j.ejphar.2006.09.024. PMID   17067572.
  4. 1 2 Kimmel HL, O'Connor JA, Carroll FI, Howell LL (January 2007). "Faster onset and dopamine transporter selectivity predict stimulant and reinforcing effects of cocaine analogs in squirrel monkeys". Pharmacology, Biochemistry, and Behavior. 86 (1): 45–54. doi:10.1016/j.pbb.2006.12.006. PMC   1850383 . PMID   17258302.
  5. ↑ Sofuoglu M, Kosten TR (March 2006). "Emerging pharmacological strategies in the fight against cocaine addiction". Expert Opinion on Emerging Drugs. 11 (1): 91–98. doi:10.1517/14728214.11.1.91. PMID   16503828. S2CID   9675495.
  6. ↑ Kimmel HL, Negus SS, Wilcox KM, Ewing SB, Stehouwer J, Goodman MM, et al. (September 2008). "Relationship between rate of drug uptake in brain and behavioral pharmacology of monoamine transporter inhibitors in rhesus monkeys". Pharmacology, Biochemistry, and Behavior. 90 (3): 453–462. doi:10.1016/j.pbb.2008.03.032. PMC   2453312 . PMID   18468667.
  7. ↑ Howell LL, Carroll FI, Votaw JR, Goodman MM, Kimmel HL (February 2007). "Effects of combined dopamine and serotonin transporter inhibitors on cocaine self-administration in rhesus monkeys". The Journal of Pharmacology and Experimental Therapeutics. 320 (2): 757–765. doi:10.1124/jpet.106.108324. PMID   17105829. S2CID   9205978.
  8. ↑ Czoty PW, Martelle JL, Carroll FI, Nader MA (September 2010). "Lower reinforcing strength of the phenyltropane cocaine analogs RTI-336 and RTI-177 compared to cocaine in nonhuman primates". Pharmacology, Biochemistry, and Behavior. 96 (3): 274–8. doi:10.1016/j.pbb.2010.05.017. PMC   2907452 . PMID   20580733.
  9. ↑ Andersen ML, Sawyer EK, Carroll FI, Howell LL (April 2012). "Influence of chronic dopamine transporter inhibition by RTI-336 on motor behavior, sleep, and hormone levels in rhesus monkeys". Experimental and Clinical Psychopharmacology. 20 (2): 77–83. doi:10.1037/a0026034. PMC   3302935 . PMID   22023668.
  10. ↑ Carroll FI, Kosten TR, Buda JJ, Wang L, Walters BB (10 July 2018). "A Double-Blind, Placebo-Controlled Trial Demonstrating the Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of RTI-336". Frontiers in Pharmacology. 9: 712. doi: 10.3389/fphar.2018.00712 . PMC   6048956 . PMID   30042675.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.